Psyence Biomedical Ltd. (Nasdaq: PBM), also known as Psyence BioMed, is a biopharmaceutical and life sciences biotechnology company focused on nature-derived psilocybin and ibogaine-based psychedelic medicine. Its news flow reflects activity across clinical development, manufacturing, capital markets, and strategic partnerships.
Readers of the PBM news page can expect updates on the company’s Phase IIb clinical trial evaluating psilocybin-assisted psychotherapy for Adjustment Disorder in palliative care or in patients with cancer. News releases describe milestones such as patient dosing, expansion of clinical sites in Australia, and ethics approvals for the use of PsyLabs’ psilocybin product in the trial.
The company also issues announcements on its ibogaine operations and supply chain, including the establishment of sustainable iboga bark sourcing in Africa and the production of GMP-compliant, high-purity ibogaine hydrochloride (Ibogaine HCl) and Total Alkaloid Extracts through its partner PsyLabs. These updates highlight progress in securing psychedelic active pharmaceutical ingredients for clinical and therapeutic markets.
Other PBM news items cover strategic investments and financial decisions, such as follow-on investments in PsyLabs, share consolidation (reverse stock split) actions, and capital management frameworks that include potential share repurchase programs, as described by the company. Communications may also address leadership changes, board appointments, and corporate governance developments disclosed in conjunction with SEC filings.
In addition, Psyence BioMed publishes news on its psilocybin longevity research initiative, which examines biological markers associated with aging, and on its broader positioning in the emerging psychedelics and longevity sectors. Investors and observers who follow PBM news can use this page to track the company’s clinical progress, manufacturing capabilities, and regulatory and capital markets updates over time.
Psyence BioMed (NASDAQ:PBM), a biopharmaceutical company focused on nature-derived psilocybin and ibogaine therapies for mental health, will present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The conference will be held at the Lotte New York Palace Hotel in New York City and virtually.
CEO Dr. Neil Maresky will present the company's business strategy and pipeline. The virtual presentation will be available on-demand starting September 5, 2025, at 7:00 AM EST. Additionally, the company will host a separate webinar featuring its Scientific Advisory Board on September 16, 2025, at 12:00 PM EST to discuss ongoing clinical development programs and strategic initiatives.
[]Psyence BioMed (NASDAQ: PBM) provided a comprehensive corporate update highlighting significant progress across multiple fronts. The company reported a strong cash position of $11.4 million with no outstanding debt and successfully regained Nasdaq compliance following a 1-for-7.97 reverse stock split.
Key developments include protocol amendments to expand patient eligibility in clinical trials, activation of three clinical sites, and advancement of their Alcohol Use Disorder (AUD) study. The company strengthened its strategic alliance with PsyLabs, achieving GMP-aligned Ibogaine Total Alkaloid extract production. PBM is positioning itself in the projected $3.3 billion psychedelics market by 2031, focusing on developing naturally derived psychedelic therapies for mental health conditions.
Psyence BioMed (Nasdaq: PBM) announced that its strategic partner, PsyLabs, has successfully produced a GMP-aligned Ibogaine Total Alkaloid extract meeting food-grade consumption safety standards. This achievement follows PBM's strategic equity investments in PsyLabs during 2024 and 2025.
The breakthrough represents a significant milestone in producing high-quality psychedelic APIs, with PsyLabs' extract passing third-party laboratory verification. The company is expanding its chemistry production facilities to meet growing demand for Ibogaine HCL, Psilocybin Isolate, and other 90% purity SKUs derived from Iboga and Mushrooms.
The products will be available to licensed research institutions and developers globally, ensuring reliable and ethical sourcing of psychedelic compounds.
Psyence BioMed (NASDAQ: PBM) has finalized a service agreement with Southern Star Research, an award-winning Australian CRO, to manage their Phase IIb clinical trial investigating psilocybin-assisted psychotherapy for Adjustment Disorder in cancer patients. The double-blind, placebo-controlled study will enroll 87 participants to assess three doses of psilocybin combined with psychotherapy.
Southern Star Research, recipient of the 2024 Asia-Pacific Competitive Strategy Leadership Award, brings 14 years of expertise in oncology and mental health trials. They will oversee full trial management, including clinical monitoring, project management, and data handling. The study addresses a significant unmet need, as Adjustment Disorder affects up to 19% of cancer patients.
Additionally, FDA Commissioner Marty Makary has expressed support for psychedelic medicine, promising an "expeditious and rapid review" of clinical data from psychedelic trials under the Trump administration.
Psyence BioMed (NASDAQ: PBM) has received a notification from Nasdaq on April 16, 2025, indicating non-compliance with the minimum bid price requirement of $1.00 per share. The company's stock price remained below this threshold for 30 consecutive business days from March 5 through April 15, 2025.
Following a previous monitoring period granted on December 20, 2024, this notification constitutes a Staff Delisting Determination. PBM plans to appeal and request a hearing, which will temporarily stay the suspension of trading and delisting.
To address this issue, shareholders approved a reverse stock split at a Special Meeting on April 16, 2025, with the Board of Directors setting a final ratio of 1-for-7.97. While trading continues under 'PBM', there is no guarantee the company will successfully appeal or regain compliance with Nasdaq listing requirements.
Psyence BioMed (NASDAQ: PBM) has announced a USD $500,000 follow-on investment in PsyLabs, strengthening their partnership in psychedelic medicine development. This builds upon their September 2024 agreement where PBM acquired an 11.13% equity stake in PsyLabs.
The investment includes two key components:
- An exclusive, royalty-bearing IP licensing agreement for pharmaceutical-grade, EU-GMP, nature-derived psilocybin supply
- An exclusive right of first refusal for worldwide supply of pharmaceutical-grade, nature-derived Ibogaine
The partnership focuses on developing treatments for Substance Use Disorders (SUD), including Alcohol Use Disorder (AUD). PsyLabs will provide Psyence BioMed with high-quality psychedelic compounds to support their clinical pipeline and therapeutic development efforts. The deal is subject to definitive agreements and regulatory approvals.
Psyence BioMed (NASDAQ: PBM) has signed a Letter of Intent with Southern Star Research, an Australian contract research organization, to expand its Phase IIb clinical trial for psilocybin-assisted therapy. The trial focuses on treating adjustment disorder in cancer patients.
The partnership aims to accelerate the clinical trial timeline by leveraging Southern Star Research's national oncology and mental health network. Adjustment disorder, the seventh most frequently diagnosed psychiatric condition globally, currently lacks FDA-approved pharmaceutical treatments.
The company is transitioning trial management responsibilities from iNGENū CRO to Southern Star Research to ensure operational efficiency. A corporate webinar discussing the new agreement is scheduled for April 10, 2025, at 12:00 PM EST.